1994
DOI: 10.1038/ng0794-362
|View full text |Cite
|
Sign up to set email alerts
|

Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis

Abstract: Although first generation recombinant adenoviruses, deleted of sequences spanning E1a and E1b, have been useful for in vivo applications of gene therapy, expression of the recombinant gene has been transient and often associated with the development of inflammation. We show that with first generation adenovirus-mediated gene transfer to the mouse lung, viral proteins are expressed leading to destructive cellular immune responses and repopulation of the lung with nontransgene containing cells. Second generation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

9
287
1

Year Published

1997
1997
2000
2000

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 448 publications
(297 citation statements)
references
References 28 publications
9
287
1
Order By: Relevance
“…First, direct toxicity to myofibers may result from either exposure to AdV capsid proteins 17,18 delivered in the initial inoculum or interference with normal cellular function by factors such as low-grade de novo expression of adenoviral genes. [19][20][21] Second, host immune responses directed against AdV-infected cells and attendant elimination of transduced myofibers can lead to adverse effects on force-generating capacity. 11,12 Third, the use of germ cell correction of the genetic abnormality to prevent disease onset in transgenic animals differs substantially from the anticipated clinical scenario, which would involve treating individuals with established disease of varying degrees of severity.…”
Section: Discussionmentioning
confidence: 99%
“…First, direct toxicity to myofibers may result from either exposure to AdV capsid proteins 17,18 delivered in the initial inoculum or interference with normal cellular function by factors such as low-grade de novo expression of adenoviral genes. [19][20][21] Second, host immune responses directed against AdV-infected cells and attendant elimination of transduced myofibers can lead to adverse effects on force-generating capacity. 11,12 Third, the use of germ cell correction of the genetic abnormality to prevent disease onset in transgenic animals differs substantially from the anticipated clinical scenario, which would involve treating individuals with established disease of varying degrees of severity.…”
Section: Discussionmentioning
confidence: 99%
“…16 However, adenoviruses show inherent immunological problems, 17 resulting in reduction of gene expression on repeated application. Alterations in the adenovirus sero-type, 18 blocking antibodies to the CD40 antigen 19 and increasing deletions of the viral genome 20 have begun to address this problem. Both preclinical studies in primates and cotton rats 21,22 and clinical trials in man show adenoviruses are capable of producing an acute T cell-mediated inflammatory response.…”
Section: Introductionmentioning
confidence: 99%
“…To circumvent vector-mediated cytotoxicity several new types of vectors have been developed including those with deletions in regions E2 or E4 24,26,27,29,38 and helper-dependent Ads. 30,[39][40][41][42][43] To minimize difficulties associated with contaminating helper virus, a Cre/loxP helper-dependent system was developed.…”
Section: Discussionmentioning
confidence: 99%
“…However, propagation of these vectors is complicated by the further requirement for E2 and E4 protein expression in the complementing host cells, and improved tolerance has not yet been demonstrated. [22][23][24][25][26][27][28][29] Recently, a system has been developed for the production of helper-dependent Ad vectors (hdAd) that are deleted for most adenovirus coding sequences. 30 In this system, the helper virus contains a packaging signal flanked by loxP sites.…”
Section: Introductionmentioning
confidence: 99%